drugset
drugset / Trial / NCT03472963

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

NCT03472963 ↗

Phase 1 Completed 35 enrolled Emory University Centers for Disease Control and Prevention · collab
Non-randomizedSequentialOpen-labelPrevention

Summary

This study is being conducted to determine if the uptake of anti-HIV medications called Genvoya® and darunavir is different at several body sites, including mucosal tissues.

Timeline

Start
2018-04-27
Primary completion
2019-03-29
Completion
2019-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 800 mg Oral
Subject Genvoya Unknown — Oral

Indications

HIV infectious disease